Introduction to Health Technology Assessment and Challenges for Neurological Conditions

Current Status
Not Enrolled
Price
Free
Get Started

S7M1-Intro to HTA web 1

Kindly Supported By

Presenter: David Schwicker
Duration: 50 mins
Sections: 3

In this module the audience will learn what Health Technology Assessment (HTA) is at national and EU level, how it is applied to healthcare decision-making and the viewpoints of the stakeholders involved in the HTA space. This module also covers how the uncertainty around neurological disorders influences the current access disparities, and how patient involvement can lead to more accurate decision-making in the value chain, ultimately supporting research and innovation and quality of life.

In the first module of this series you will learn:

  • Section 1:
    • What Health Technology Assessment (HTA) is
    • Two main HTA components – Assessment and Appraisal
    • HTA and healthcare decision-making
    • The 4 viewpoints of value
  • Section 2:
    • Difference in uncertainties between regulators and HTA bodies
    • Clinical uncertainties and HTA
    • Neurological disorders and uncertainty
    • State of play – Access disparities
  • Section 3:
    • Value and the complexity of precision medicine
    • Patient Involvement throughout the value chain: Health-related Quality of Life (HRQoL) in neurological disorders
    • Challenges to research

Now, let’s continue…

 

Sources / further reading:

 

EUCAPA trainings

Joint effort of EURORDIS, EPF and UMIT TIROL University for Health Sciences and Technology

1. Introductory training (LAUNCHED November): 

https://www.eucapa.eu/trainings/introductory

  • For a larger patient community / national patient organisations interested to participate in JSC and JCA
  • Time needed: 2h. It aims to train 250 – 500 patients. Module 4 of the Introductory training focuses on Scoping process_PICO.

2. Fast-track training: for patients who are interested to participate in a JSC or JCA.

  • Time needed: 8h. It aims to train 250 patients.
  • First training dates, registration needs to be made in advance: January 23, February 20, April 16 

3. Extended training: People who want to deal with HTA in more depth as patient advocates, at EU and national level.  

  • Time needed: 4 days. It involves more in-depth exercises, 6h online course + 3-day-live course at UMIT TIROL. It aims to train 100 patients.
  • First training date: March 5-7 2024

Contact personjulien.delaye@eurordis.org

 

EUPATI trainings

EUPATI is currently leading a training project entitled ‘HTA4Patients’, funded by the European Union, until end of 2025. The work is conducted in collaboration with EUPATI National Platforms, EUPATI Fellows, EUPATI Partners across Patient Organisations, Academia and Industry, as well as the Workgroup of European Cancer Patient Advocacy Networks (WeCan), HTAi, ISPOR and national HTA bodies. HTA4Patients will enhance the education, training and information that EUPATI already provides on HTA via its Open Classroom and Toolbox empowering patients and patient organisations to play a vital role in the implementation of the new framework.

I understand they will also launch an EUPATI Open Classroom online training course on the EU HTAR by September 2024 (in English), to be translated into 5 other EU languages by August 2025. From September 2024 onwards, they will also have available a customizable webinar package & at least 12 online training sessions for different patient communities.

Dedicated website: https://eupati.eu/hta4patients/

Contact person: Maria Dutarte -  maria.dutarte@eupati.eu